BTIG analyst Marie Thibault lowered the firm’s price target on Inari Medical to $86 from $93 and keeps a Buy rating on the shares after its Q4 results. The company’s revenue was helped by healthy core VTE – venous thromboembolism – volumes, with traction with new products and strong outside U.S. sales, but the DoJ investigation may be an overhang, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NARI:
- Inari Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
- Inari Medical initiated with a Buy at Needham
- Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance
- Inari Medical sees FY24 revenue $580M-$595M, consensus $583.07M
- Inari Medical sees 2023 revenue at least $493.5M, consensus $491.37M